Hoth Therapeutics Taps Lantern Pharma's PredictBBB.ai Platform -- Breakthrough AI With 94% Accuracy Driving Next-Gen Drug Development
Hoth Therapeutics (NASDAQ: HOTH) has announced its adoption of Lantern Pharma's PredictBBB.ai platform, an artificial intelligence tool boasting 94% accuracy in predicting blood-brain barrier permeability. This strategic move aims to enhance Hoth's drug development process by leveraging AI technology to determine whether drug candidates can effectively cross the blood-brain barrier.
The partnership with Lantern Pharma's RADR® AI platform positions Hoth to potentially accelerate drug development timelines, reduce risks, and streamline candidate selection. The technology addresses a major challenge in drug development while potentially creating faster regulatory pathways and higher value inflection points for Hoth's pipeline.
Hoth Therapeutics (NASDAQ: HOTH) ha annunciato l'adozione della piattaforma PredictBBB.ai di Lantern Pharma, uno strumento di intelligenza artificiale che vanta una precisione del 94% nella previsione della permeabilità della barriera emato-encefalica. Questa scelta strategica punta a migliorare il processo di sviluppo dei farmaci di Hoth, sfruttando l'AI per valutare se i candidati farmacologici riescono a oltrepassare efficacemente la barriera emato-encefalica.
La collaborazione con la piattaforma RADR® AI di Lantern Pharma mette Hoth nella posizione di potenzialmente accelerare i tempi di sviluppo, ridurre i rischi e snellire la selezione dei candidati. La tecnologia affronta un problema cruciale nello sviluppo farmaceutico e potrebbe favorire percorsi normativi più rapidi e punti di svolta di maggior valore per il portafoglio di Hoth.
Hoth Therapeutics (NASDAQ: HOTH) ha anunciado la adopción de la plataforma PredictBBB.ai de Lantern Pharma, una herramienta de inteligencia artificial que presume una precisión del 94% para predecir la permeabilidad de la barrera hematoencefálica. Esta decisión estratégica busca optimizar el proceso de desarrollo de fármacos de Hoth, usando IA para determinar si los candidatos farmacológicos pueden cruzar eficazmente la barrera hematoencefálica.
La alianza con la plataforma RADR® AI de Lantern Pharma posiciona a Hoth para acelerar potencialmente los plazos de desarrollo, reducir riesgos y simplificar la selección de candidatos. La tecnología aborda un reto importante en el desarrollo de medicamentos y podría abrir vías regulatorias más rápidas y puntos de inflexión de mayor valor para la cartera de Hoth.
Hoth Therapeutics (NASDAQ: HOTH)는 혈액뇌장벽 투과성을 예측하는 데 있어 94%의 정확도를 자랑하는 인공지능 도구인 Lantern Pharma의 PredictBBB.ai 플랫폼을 도입했다고 발표했습니다. 이번 전략적 조치는 후보 약물이 혈액뇌장벽을 효과적으로 통과할 수 있는지를 AI로 판단해 Hoth의 약물 개발 과정을 개선하려는 목적입니다.
Lantern Pharma의 RADR® AI 플랫폼과의 협력은 Hoth가 개발 기간을 가속화하고 리스크를 줄이며 후보물질 선정을 간소화할 수 있는 기회를 제공합니다. 이 기술은 약물 개발의 주요 과제를 해결하면서 규제 절차를 단축하고 Hoth 파이프라인의 가치 전환점을 앞당길 가능성이 있습니다.
Hoth Therapeutics (NASDAQ: HOTH) a annoncé l'adoption de la plateforme PredictBBB.ai de Lantern Pharma, un outil d'intelligence artificielle affichant une précision de 94% pour prédire la perméabilité de la barrière hémato-encéphalique. Cette initiative stratégique vise à améliorer le processus de développement des médicaments de Hoth en utilisant l'IA pour déterminer si les candidats-médicaments peuvent traverser efficacement la barrière hémato-encéphalique.
Le partenariat avec la plateforme RADR® AI de Lantern Pharma place Hoth en position de potentiellement accélérer les délais de développement, réduire les risques et rationaliser la sélection des candidats. La technologie répond à un défi majeur du développement pharmaceutique et pourrait ouvrir des voies réglementaires plus rapides ainsi que des points d'inflexion de valeur pour le pipeline de Hoth.
Hoth Therapeutics (NASDAQ: HOTH) hat die Einführung der PredictBBB.ai-Plattform von Lantern Pharma bekanntgegeben, eines KI-Tools, das eine 94%ige Genauigkeit bei der Vorhersage der Blut-Hirn-Schranken-Permeabilität ausweist. Dieser strategische Schritt soll Hoths Wirkstoffentwicklungsprozess verbessern, indem KI eingesetzt wird, um zu beurteilen, ob Wirkstoffkandidaten die Blut-Hirn-Schranke effektiv überwinden können.
Die Partnerschaft mit Lantern Pharmas RADR® AI-Plattform positioniert Hoth so, dass das Unternehmen Entwicklungszeiten potenziell verkürzen, Risiken reduzieren und die Kandidatenauswahl optimieren kann. Die Technologie adressiert eine zentrale Herausforderung in der Wirkstoffentwicklung und könnte schnellere Zulassungswege sowie höherwertige Wendepunkte für Hoths Pipeline ermöglichen.
- AI platform demonstrates high accuracy rate of 94% in blood-brain barrier permeability prediction
- Technology expected to reduce development risks and accelerate drug development timelines
- Potential for cost reduction in drug development process
- Strategic positioning for faster regulatory pathways
- None.
Insights
Hoth's adoption of Lantern's AI blood-brain barrier prediction platform could significantly accelerate CNS drug development and reduce costly failures.
Hoth Therapeutics' strategic adoption of Lantern Pharma's PredictBBB.ai platform represents a potentially significant advancement in their drug development capabilities. The platform's 94% accuracy in predicting blood-brain barrier (BBB) permeability addresses one of the most critical challenges in central nervous system (CNS) drug development. The blood-brain barrier historically functions as both a protective mechanism for the brain and a major obstacle for therapeutic delivery, with approximately 98% of small molecule drugs and nearly all large molecule therapeutics failing to penetrate this barrier effectively.
This AI implementation could substantially reduce development costs and timelines by enabling earlier elimination of non-viable candidates. Traditional methods of assessing BBB permeability rely on expensive and time-consuming in vitro and animal studies that often yield variable results. By front-loading this critical assessment through computational prediction, Hoth can prioritize molecules with higher probability of success before committing significant resources to their development.
For Hoth's pipeline, this technology may enable more efficient development of therapies targeting neurological conditions, potentially expanding their addressable markets. The focus on BBB permeability suggests Hoth may be strengthening or expanding their CNS portfolio, which would represent a strategic pipeline evolution. While the announcement doesn't specify financial terms, the implementation of AI-driven decision-making reflects an industry-wide shift toward computational approaches that reduce traditional R&D inefficiencies, positioning Hoth to potentially achieve development milestones with greater capital efficiency.
PredictBBB.ai, part of Lantern's RADR® AI platform, is a game-changing technology designed to eliminate one of the most significant bottlenecks in drug development: determining whether a candidate can cross the blood-brain barrier. By deploying this AI-driven solution, Hoth expects to streamline candidate selection, reduce development risk, and accelerate timelines toward transformative therapies.
"At Lantern Pharma, we're very enthused by the early adoption of our PredictBBB.ai platform by innovators like Hoth Therapeutics. This online service, which is a part of our RADR platform, has the potential to be a game-changer in CNS drug development. This cutting-edge AI tool, with its
Strategic Impact for Hoth Therapeutics
The ability to cross the blood-brain barrier is a critical success factor for drug candidates. With PredictBBB.ai, Hoth gains access to AI-powered insights that increase precision and reduce uncertainty, potentially creating faster regulatory pathways and higher value inflection points for its pipeline.
"Hoth is committed to deploying disruptive technologies like AI to enhance precision in drug development," said Robb Knie, Chief Executive Officer Hoth Therapeutics. "Our integration of Lantern's PredictBBB.ai tool aligns with our mission to deliver life-changing therapies while driving efficiency, reducing costs, and unlocking new opportunities for patients and shareholders alike."
About Hoth Therapeutics, Inc.
Hoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life. We are a catalyst in early-stage pharmaceutical research and development, elevating drugs from the bench to pre-clinical and clinical testing. Utilizing a patient-centric approach, we collaborate and partner with a team of scientists, clinicians, and key opinion leaders to seek out and investigate therapeutics that hold immense potential to create breakthroughs and diversify treatment options. To learn more, please visit https://ir.hoththerapeutics.com/ .
Forward-Looking Statement
This press release includes forward-looking statements based upon Hoth's current expectations, which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties, and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; the timing and costs of clinical trials, and the timing and costs of other expenses; market acceptance of our products; the ultimate impact of the current coronavirus pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems, or the global economy as a whole; our intellectual property; our reliance on third-party organizations; our competitive position; our industry environment; our anticipated financial and operating results, including anticipated sources of revenues; our assumptions regarding the size of the available market, benefits of our products, product pricing, and timing of product launches; management's expectation with respect to future acquisitions; statements regarding our goals, intentions, plans, and expectations, including the introduction of new products and markets; and our cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place reliance on these forward-looking statements, which include words such as "could," "believe," "anticipate," "intend," "estimate," "expect," "may," "continue," "predict," "potential," "project" or similar terms, variations of such terms, or the negative of those terms. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section titled "Risk Factors" in Hoth's most recent Annual Report on Form 10-K and Hoth's other filings made with the U. S. Securities and Exchange Commission. All such statements speak only as of the date made. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates, and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance, or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events, or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.
Investor Contact:
LR Advisors LLC
Email: investorrelations@hoththerapeutics.com
www.hoththerapeutics.com
Phone: (678) 570-6791
View original content to download multimedia:https://www.prnewswire.com/news-releases/hoth-therapeutics-taps-lantern-pharmas-predictbbbai-platform--breakthrough-ai-with-94-accuracy-driving-next-gen-drug-development-302545700.html
SOURCE Hoth Therapeutics, Inc.
FAQ
What is the accuracy rate of Lantern Pharma's PredictBBB.ai platform that Hoth Therapeutics (NASDAQ: HOTH) is adopting?
How will PredictBBB.ai benefit Hoth Therapeutics' drug development process?
What is the main challenge that PredictBBB.ai addresses in drug development?
Who are the key executives involved in the Hoth Therapeutics and Lantern Pharma collaboration?
What is the strategic impact of PredictBBB.ai for Hoth Therapeutics (HOTH)?
